ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Inclusion Criteria:

- patients >=18 years of age;

- CHC infection (genotype 2 or 3);

- liver biopsy (in <24 calendar months of first dose), with results consistent with CHC
infection;

- use of 2 forms of contraception during study and 6 months after the study in both men
and women.

Exclusion Criteria:

- women who are pregnant or breastfeeding;

- male partners of women who are pregnant;

- conditions associated with decompensated liver disease;

- other forms of liver disease, including liver cancer;

- human immunodeficiency virus infection;

- previous treatment with an IFN, pegylated IFN, ribavirin, viramidine, levovirin, or
amantadine.